SCHEMBL3531848

SCHEMBL3531848

O=c1[nH]nc(Cl)cc1-c1nc2ccccc2[nH]1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.61
PDGFRB P09619 1/20 0.61
FGFR1 P11362 1/20 0.61
GSK3B P49841 1/20 0.58
NPC1 O15118 8/20 0.55
RAB9A P51151 8/20 0.55
ALDH1A1 P00352 6/20 0.55
KDM4E B2RXH2 5/20 0.55
GPR55 Q9Y2T6 1/20 0.55
BTK Q06187 1/20 0.54
GBA1 P04062 1/20 0.54
AMY1A P0DUB6 2/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
NPSR1 Q6W5P4 3/20 0.50
PKM P14618 2/20 0.50
HSD17B10 Q99714 2/20 0.50
ABCB11 O95342 1/20 0.50
TP53 P04637 1/20 0.50
ADORA3 P0DMS8 1/20 0.49
ADORA1 P30542 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2943434 0.86 AMY1A (0.54) NPC1ALDH1A1KDM4EAMY1ASMN1; SMN2
SCHEMBL3539812 0.82 AMY1A (0.45) KDRPDGFRBFGFR1GSK3BNPC1
SCHEMBL2949340 0.82 ALDH1A1 (0.51) KDRPDGFRBFGFR1GSK3BNPC1
SCHEMBL3540845 0.80 GSK3B (0.61) KDRPDGFRBFGFR1GSK3BNPC1
SCHEMBL3542928 0.79 GSK3B (0.57) KDRPDGFRBFGFR1GSK3BNPC1
SCHEMBL2641186 0.79 GSK3B (0.66) KDRPDGFRBFGFR1GSK3BNPC1
SCHEMBL4300569 0.78 KDR (0.74) KDRPDGFRBFGFR1GSK3BNPC1
SCHEMBL29394784 0.78 KDR (0.74) KDRPDGFRBFGFR1GSK3BNPC1
SCHEMBL3501686 0.78 KDR (0.74) KDRPDGFRBFGFR1GSK3BNPC1
SCHEMBL3535301 0.78 GSK3B (0.65) KDRPDGFRBFGFR1GSK3BNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727989-B2 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-06-01 US claimed
US-7727989-B2 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-06-01 US disclosed
US-7727989-B2 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-06-01 US disclosed
US-7727989-B2 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-06-01 US disclosed
EP-1725543-B1 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS SANOFI AVENTIS DEUTSCHLAND (DE) 2007-11-28 EP disclosed
US-20070072866-A1 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-03-29 US disclosed
US-20070072866-A1 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-03-29 US disclosed
US-20070072866-A1 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-03-29 US disclosed
EP-1725543-A1 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS Sanofi-Aventis Deutschland GmbH (DE) 2006-11-29 EP disclosed
WO-2005085230-A1 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072866-A1 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS GSK3B, GSK3A, PYGB KDR 2532/4885PDGFRB 579/4885FGFR1 1854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.